A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany

By Beard Stephen   Maciver Fiona   Clouth Johannes   Rüther Eckart  

The European Journal of Health Economics, Vol. 7, Iss. 3, 2006-09 ,pp. : 165-172

Springer Publishing Company

Access to resources Recommend Favorite

Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia

By Zhao Zhongyun  

Current Medical Research and Opinion, Vol. 20, Iss. 7, 2004-07 ,pp. : 1039-1048

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia

By Ascher-Svanum Haya   Stensland Michael D.   Peng Xiaomei   Faries Douglas E.   Stauffer Virginia L.   Osuntokun Olawale O.   Kane John M.  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 115-122

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of a multifactorial approach to reduce the prevalence of pressure injuries in regional Australian acute inpatient care settings

By  

INTERNATIONAL WOUND JOURNAL, Vol. 15, Iss. 1, 2018-02 ,pp. : 95-105

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population

By Yu Andrew P.   Ben-Hamadi Rym   Birnbaum Howard G.   Atanasov Pavel   Stensland Michael D.   Philips Glenn  

Current Medical Research and Opinion, Vol. 25, Iss. 3, 2009-03 ,pp. : 755-764

Informa Healthcare

Access to resources Recommend Favorite